These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Adjuvant treatment for stage I of testicular germ cell tumours].
    Author: Lakomý R, Poprach A, Nēmecek R, Vyskocil J, Ondrová B, Kocák I, Kocáková I, Rehák Z, Vyzula R.
    Journal: Klin Onkol; 2009; 22(1):22-6. PubMed ID: 19534436.
    Abstract:
    BACKGROUND: Testicular germ cell tumors (TGCT) are the most frequent malignancy seen in young men. More than 95% of patients diagnosed with early stage TGCT are cured. In management of stage I seminoma there are several treatment options, including adjuvant radiotherapy, adjuvant chemotherapy with one cycle of carboplatin or surveillance. Patients with stage I nonseminoma are treated with adjuvant chemotherapy, with nerve sparing retroperitoneal lymph node dissection or surveillance being considered another treatment alternatives for stage I disease. METHODS AND RESULTS: Fifty five patients with stage I TGCT were diagnosed and treated in Masaryk Memorial Cancer Institute between January 2000 to December 2004. In a retrospective analysis, we reviewed treatment outcome and treatment strategy used in these patients. Patients characteristics also included histological subtype, risk status, age at the time of diagnosis, relapse rate, delayed toxicity, etc. Despite the small number of patients included in the analysis (55), there was observed a clear preference toward adjuvant radiotherapy in seminoma patients (95%) and adjuvant chemotherapy in nonseminoma patients (97%). During median follow up (5,6 years in seminoma group, 5,7 years in nonseminoma group) only two patients experienced relapse of disease in the seminoma group and none in the nonseminoma group. One patient died of metastatic colorectal cancer. Acute toxicity was acceptable, with no treatment related death. The long- term side effects were not significant (no grade 3 or 4 toxicity). CONCLUSION: The achieved cure rates were high, with acceptable toxicity. The role of adjuvant chemotherapy with carboplatin in stage I seminoma remains controversial. Further management of TGCT should be guided by complete and correct assessment of known risk factors to ensure the potential for cure.
    [Abstract] [Full Text] [Related] [New Search]